Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 20 for “"irinotecan"”.
-
The role of matrix metalloproteinases and their inhibitors in irinotecan-induced oral mucositis: an animal model.
Background: Chemotherapy-induced oral mucositis is defined as damage of oral mucosa caused by unwanted detrimental effects of the cytotoxic chemotherapy. Oral mucositis presents as widespread painful ulcerations and erythematous eruptions and occurs in between 40-100% of all patients undergoing …
-
Investigations into the Mechanisms that Are Responsible for Reduction in Colonic SN-38 Exposure
Statement of the Problem: Irinotecan is used as a single agent or in combination with other drugs to treat metastatic colorectal cancer. However, its usage is largely limited as it exhibits late onset diarrhea in 30-40% of the patient population due to the high accumulation of SN-38 in colon. It …
-
The Role of Multi-Drug Resistance Associated Protein 4 and P-glycoprotein in Resistance of Neuroblastoma to Topotecan and Irinotecan
… The camptothecin analogs topotecan and irinotecan have been identified as successful cytotoxic agents. For topotecan, pharmacokinetically guided dosing to achieve a systemic exposure associated with preclinical anti-tumor activity in neuroblastoma xenograft models is feasible and has …
-
Development and In-Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma
… liposomes for the delivery of gemcitabine and irinotecan hydrochloride in pancreatic cancer.|A simple HPLC method was developed for simultaneous quantification of gemcitabine and irinotecan in aqueous medium. The accuracy (% error < 10%) and precision (% RSD < 5%) of the methods followed USP …
-
Tailored chemotherapy based on genomic polymorphisms for metastatic colorectal cancer treated with 5-fluorouracil plus oxaliplatin or irinotecan in Korean patients
배경: 옥살리플라틴과 이리노테칸은 전이성 대장암 환자에서 5-FU와 함께 투여하여 FOLFOX 또는 FOLFIRI용법으로 일차치료로서 가장 많이 사용되는 항암제이다. 본 연구의 목적은 전이성 대장암 환자에서 전향적 연구로서 항암제와 연관된 유전자 다형성을 분석하고 환자에 맞는 약제를 선택하여 일차치료를 진행하여 이에 대한 반응도를 알아보기로 하였다. 방법: 50명의 전이성 대장암 환자에서 말초혈액을 통해 유전자 다형성을 분석하였다. PCR-based RFLP 방법을 사용하여 TS, MTHFR-977, XPD-751, …
-
Molecular Considerations In The Design Of Novel Alpha/Beta Hydrolase Inhibitors
… of many esterified drugs. The chemotherapy drug irinotecan used for treatment of colorectal cancer is metabolized to SN-38, the active drug metabolite, by two CE isozymes CES1 (localized in the liver) and CES2 (localized in the small intestines). CES2's ability to activate irinotecan at a faster …
-
Formulation of targeted drug-loaded nanoparticles for lung cancer therapy
… then subjected to entrapment of cisplatin and irinotecan, filter centrifugation and tangential flow filtration (TFF) methods, scaleup fabrication process, entrapment efficiency and release studies, lyophilisation and invitro assay against A549 cells. It was also observed that these stable …
-
Lgr5 Regulation of Stat3 Signaling and Drug Resistance In Colorectal Cancer
… we also found that LGR5+ CRC cells treated with irinotecan or LGR5-targeted ADCs, converted these cells to an LGR5- state with increased MET/STAT3 activation. LGR5 overexpression in a CRC cell line which doesn’t endogenously express LGR5, resulted in decreased phosphorylation of MET/STAT3 and …
-
Synthesis and characterization of pH/temperature dual sensitive multiblock copolymer for drug delivery
… degradation and drug release with nile red and irinotecan. The ketal linker connecting Pluronic® was cleaved and resulted in smaller molecular weight strain causing change in sol-gel transition temperature and critical micelle concentration. This mechanism confers the synthesized polymer with …
-
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
… The improved efficacy of newer oxaliplatin- and irinotecan-based chemotherapeutic regimens combined with the low incidence of tumor related complications has led surgeons and oncologists to question the utility and, when indicated, the timing of elective resection of the primary tumor in …
-
The Role of Tak1 In Pancreatic Cancer Development
… activity of gemcitabine, oxaliplatin, or irinotecan on pancreatic cancer cells. These findings highlighted that TAK1 could be a potential therapeutic target for pancreatic cancer.</p> <p>We also demonstrated that TAK activity is regulated by its binding protein TAB1. We defined a minimum …
-
Synthesis and Characterization of Redox-Sensitive Polymer and Prodrug for Targeted Drug Delivery
… a potent metabolite of irinotecan (CPT-11), has been extensively investigated in the past for direct usage in order to fully exploit its cytotoxic potency. Here, 2,4-dinitrobenzene sulfonyl (DNS) moiety was conjugated to SN-38 to furnish a thiol-sensitive prodrug, denoted …
-
Functional contribution of epithelial to mesenchymal transition program on KRASG12D targeting efficacy in pancreatic cancer
… as gemcitabine, and FOLFIRINOX (fluorouracil, irinotecan, leucovorin, oxaliplatin), although these have been known for their low efficacy. The emergence of KRAS<sup>G12C </sup>inhibitors, Adagrasib and Sotorasib, paved the way for the development of MRTX1133, a KRAS<sup>G12D </sup>inhibitor. …
-
Design, Synthesis, and Evaluation of Novel Positron Emission Tomography Radiotracers
… that could measure the enzymatic activation of Irinotecan (CPT-11), a potent chemotherapeutic used in the treatment of colon cancer and several pediatric solid tumors. CPT-11 itself is a prodrug which is converted in vivo to SN-38, via metabolism by carboxylesterase (CE) enzymes. St. Jude …
-
Evaluating Cost Effectiveness of Precision Cancer Medicine Approaches and The Economic Burden of Colorectal Cancer
… status is not cost-effective in guiding irinotecan dosing.<br/><br/>4.The cost effectiveness of testing of KRAS/NRAS mutational status for guiding cetuximab or panitumumab therapy is inconclusive.<br/><br/>Overall, the systematic review revealed that there was a paucity of …
-
Development of novel polymeric nanoparticles for pancreatic cancer therapy
… therapy of folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) comes with significant toxicity and is only tolerable by some patients. Some improvement of the therapeutic index of existing chemotherapies may be achieved by encapsulation of chemotherapies inside …
-
Inhibition of KDM4 with QC6352 to Target High-Risk Neuroblastoma
… chemotherapeutics (vincristine and irinotecan) led to 100% complete response in MNA NB xenografts without overt toxicity and accompanied by prolongation of survival. All in all, this research offers a solid proof-of-concept that pharmacologic inhibition of KDM4 with QC6352 may be …
-
Development of novel antibody-targeted nanoparticle strategies for treatment of pancreatic cancer
… the much less potent topoisomerase 1 inhibitor, irinotecan is currently used in pancreatic cancer treatment as part of the FOLFIRINOX regimen. <br/><br/>To improve antibody conjugation a novel N-hydroxysuccinamide endcapped polymer was employed to circumvent the need for in situ EDC …
-
Identification of novel determinants of primary and acquired resistance to EGFR-targeted therapies in colorectal cancer
… IV CRC patients. The addition of oxaliplatin or irinotecan to 5-FU and folinic acid (FOLFOX and FOLFIRI respectively) was determined to increase this response rate and overall survival to 40-50% and 15-19 months respectively. These combination chemotherapeutics subsequently became the standard of …